

International Pharmaceutical and Medicinal Publications Catalogue



Featuring publications from:



Medicines & Healthcare products
Regulatory Agency



The British Pharmacopoeia 2025

The British Pharmacopoeia (BP) 2025 supersedes the BP 2024 and becomes legally effective on 1 January 2025.

The BP is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes approximately 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012. Where a BP monograph exists, medicinal products sold or supplied in the UK must comply with the relevant monograph.

All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and beyond.

Ensure you get the best value access to the information you need. Choose from a range of flexible licences and formats – including full online and offline access.

Add the BP Archive option to your standard package and receive online access to all the BP editions from 2014 to date. The Archive is a useful tool that enables you to switch between different versions of a monograph by publication to help users track what's changed.



Author: The British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare products Regulatory Agency (MHRA)

Publisher: TSO (The Stationery Office)

New for the BP 2025

- 14 new BP monographs, 32 new Ph. Eur. monographs. Including two new monographs on Paracetamol Infusion and Paracetamol Oral Solution.
- 105 amended BP monographs.
- All monographs from the Ph. Eur. 11th edition and Ph. Eur. supplements 11.1 and 11.5.
- Ph. Eur. supplements 11.6 to 11.8 included as in-year online and download product updates.

Products	Format	ISBN/SUB NO	Price
Complete Package	Six-volume printed edition Single-user* online licence Single-user* download for offline use	9780113231034	£1,000
Hard Copy	Six-volume printed edition	9780113231041	£875
Single-User Licence (SUL)	Single-user online licence*	7005139	£875
SUL + BAN	Single-user online licence*	7005140	£1,025
SUL + Archive	Single-user online licence*	7005141	£1,075
SUL + BAN + Archive	Single-user online licence*	7005142	£1,225

* These single-user licences are granted solely to the designated holder of the product within an organisation. Multi-user licences are available.

British Pharmacopoeia Multi-User Licences


Simultaneous access for two or more users across your organisation – various licence options available to suit your needs.

Our Multi-user licence will provide you with:

- A cost-effective, flexible solution tailored to your organisation's requirements
- Simultaneous access across workstations, laptops and other portable devices in any location
- Access to the full text of the BP and European Pharmacopoeia including Ph. Eur in-year updates
- Instant online access via IP recognition
- Option to add BAN
- Discounts available for academic users

Subscriptions give access from 1 January (effective date) for one year. Add the BP Archive to gain access from 1 August.

Quick set up, no shipping charges and dedicated customer and user support



Contact: Pharmahealth@williamslea.com or call +44 (0)1603 696675 to discuss your requirements

“Online access has revolutionised the way in which BP is accessed within our company. We find that it provides a really user-friendly and efficient way of navigating the content, and the multi-user licence enables our entire company to have access at a really cost-effective price.”

Ashleigh Gordon
Aesica Pharmaceuticals Ltd



Single-user online licences

- Suitable for one named user
- Access selected edition from 1 August (publication date) for 20 months
- Personalise your licence by adding the BP Archive and British Approved Names (BAN):
 - Add BP Archive to see what's changed more clearly
 - Add BAN to quickly reference adopted medicinal substance names

From £875



British Approved Names

2022

A British Pharmacopoeia publication

Incorporating International
Nonproprietary Names

A dictionary of drug names
for regulatory use in the United Kingdom

British Approved Names (BAN) 2022

The British Approved Names (BAN) is the official dictionary of names for UK medicinal substances. British Approved Names are short, distinctive names for substances for which the systematic chemical or other scientific names are too complex for convenient general use. The BAN makes an important contribution to public health by ensuring that names selected are unique. The BAN is an essential reference for all individuals and organisations working within pharmaceutical research, manufacture and regulatory affairs.

Key features

- Special attention to biological and biotechnological substances
- Key to pronunciation, symbols and abbreviations
- Cross-reference index of British Approved Names and Proprietary Names
- Guidelines for pharmaceutical trade marks
- Discontinued substances and products listed

Author: The British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare products Regulatory Agency (MHRA)

Publisher: TSO (The Stationery Office)

Products	Format	ISBN	Price
BAN 2022	Print A4 Hardback	9780113230907	£150
BAN Supplement No.1	Print A4 Hardback	9780113230945	£20
BAN Supplement No.2	Print A4 Hardback	9780113230990	£20



European Pharmacopoeia 11th Edition

The European Pharmacopoeia (Ph. Eur.) is a single reference work for the quality control of medicines in Europe. All producers of medicines or substances for pharmaceutical use must apply the quality standards of the European Pharmacopoeia for the marketing and use of these products in Europe.

The Ph. Eur. outlines preparations for pharmaceutical use of chemical, animal, human or herbal origin. It also covers biologicals, blood and plasma derivatives, vaccines and radiopharmaceutical preparations. The monographs give quality standards for all the main medicines used in Europe.


The European Pharmacopoeia is supplied as a subscription to ensure that subscribers receive all three issues of their purchase. Print supplements are non-cumulative and therefore all previous issues of an edition are required.

- New edition, legally binding in 39 European countries as of 1 January 2023 and applied in more than 130 countries worldwide.
- Continually updated and modernised to meet users' needs.
- The 11th Edition (including Supplement 11.2) of the Ph. Eur. contains:
 - 2 474 monographs (including dosage forms);
 - 387 general texts (including general monographs and methods of analysis);
 - and about 2 870 descriptions of reagents.

Author and Publisher: European Pharmacopoeia Commission, Council of Europe European Directorate for the Quality of Medicines (EDQM)

(Mac coming soon)

Products	Format	ISBN/SUB NO	Price
European Pharmacopoeia 11th Edition (includes Supplements 11.1 and 11.2)	Print	7704064	£510
European Pharmacopoeia 11th Edition (includes Supplements 11.3 - 11.5)	Print Electronic	7704065 9789999159555	£510
European Pharmacopoeia 11th Edition (includes Supplements 11.6 - 11.8)	Print Electronic	7704066 TBC	£510




Chinese Pharmacopoeia 2020 Edition - English Translation

The Pharmacopoeia of the People's Republic of China 2020 edition is the 11th edition.

It covers both traditional Chinese medicine and Western medicines. It gives descriptions and information of purity, testing, dosage, precautions, storage and strength of each drug.

The latest edition of Chinese Pharmacopoeia was released on July 2, 2020, and took effect on Dec. 30, 2020. this edition of pharmacopoeia includes 5911 monographs, 319 new additions, 3177 revisions, 10 rejections, and 6 reductions due to the merger of monographs

Formats	ISBN	Price
Print	9780118987677	£1,200



Japanese Pharmacopoeia 18th Edition - English Translation


The Japanese Pharmacopoeia is the pharmaceutical standard that the Japanese Minister of Health, Labour and Welfare (MHLW) establishes to regulate the properties and quality of drugs.

As with other pharmacopoeias, the document is revised periodically. The 18th edition (JP18) came into effect on June 7, 2021. The text is originally prepared in Japanese and translated to English after the publication of the Japanese version.

Contents include:

- General Notice - General Tests, Processes and Apparatus
- Official Monographs (A to L)
- Official Monographs (M to Z)
- Crude Drugs and Related Drugs
- Infrared Reference Spectra
- Ultraviolet-visible Reference Spectra
- General Information

Formats	ISBN	Price
Print	9784840815895	£795



German Homeopathic Pharmacopoeia (GHP) 2022 – Including 19th Supplement

This updated edition has been translated into the English language, making this widely acclaimed work available to the global community of:

- Homoeopathic manufacturers
- Homoeopathic physicians
- Non-medical practitioners
- Pharmacists and
- National registration authorities

Professionals engaged in all aspects of the manufacture, evaluation, registration or dispensing of homoeopathic substances or medicinal products now have access to a wealth of information comprising approximately 600 monographs and general texts including reagents, vehicles and excipients analytical and the very important manufacturing methods. Homoeopathic and anthroposophical manufacturing methods are included as well as the methods used in spagyrics and the production of organ-derived preparations. The analytical methods have been harmonized with the European Pharmacopoeia (Ph. Eur.) and the German Pharmacopoeia (DAB).

The loose-leaf format makes it easy for the user to keep this collection up to date.

Formats	SUB NO	Price
Looseleaf with binder holes	9783804750951	£410



British National Formulary: 88 (March 2025)

The British National Formulary (BNF) is the first choice for concise medicines information. Trusted by healthcare professionals across the world to support confident decision-making at the point of care.

The new edition (BNF 85) provides up-to-date guidance on prescribing, dispensing, and administering medicines, plus legal and professional guidelines. Access to the latest edition of the BNF is vital for healthcare professionals, as it reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.

Author: British Medical Association, Royal Pharmaceutical Society of Great Britain

Publisher: BMJ Publishing Group Ltd and Royal Pharmaceutical Society

ISBN: 9780857114822

Price: £79.00

Format: Paperback 210 x 148mm

Extent: 1984pp



BNF for Children (BNFC) 2024-2025

The BNF for Children (BNFC) 2022-2023 provides essential practical information to all healthcare professionals involved in the prescribing, dispensing, monitoring and administration of medicines to children. It addresses a significant knowledge gap in many areas of paediatric practice by providing practical information on the use of medicines in children of all ages from birth to adolescence.

Recommendations in the BNFC have been constructed on the basis of authoritative sources, emerging evidence and best practice guidelines. The content has been carefully validated by a network of paediatric experts and the process is overseen by a paediatric formulary committee.

Author: British Medical Association, Royal Pharmaceutical Society of Great Britain


Publisher: BMJ Publishing Group Ltd and Royal Pharmaceutical Society

ISBN: 9780857114792

Price: £79.00

Format: Paperback 210 x 148mm

Extent: 1408pp



Author: Royal Pharmaceutical Society

Publisher: Pharmaceutical Press

ISBN: 9780857114846

Price: £650

Format: Hardback 276 x 219mm

Extent: 4800pp


Martindale: The Complete Drug Reference 41st edition

The Complete Drug Reference provides unbiased and evaluated information on drugs and medicines in use around the world.

It is prepared by an experienced team of pharmacists and life scientists who use their professional expertise to select the most clinically relevant and appropriate information from reliable published sources, to provide an unbiased and evaluated digest of the literature.

It contains:

- Over 6,300 drug monographs
- Over 185,000 preparations
- Nearly 700 treatment reviews, with references from the published literature
- Information to help you identify medicines, the local equivalent and the manufacturer
- Herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins and poisons



Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2022 The Orange Guide

This is the tenth edition of Rules and Guidance for Pharmaceutical Manufacturers and Distributors, compiled by MHRA. Commonly known as the Orange Guide, it remains an essential reference for all manufacturers and distributors of medicines in Europe. It provides a single authoritative source of European and UK guidance, information and legislation relating to the manufacture and distribution of human medicines.

The new 2017 edition has been updated to incorporate changes and additions made to the detailed European Community guidelines on Good Manufacturing Practice (GMP) and the revised EU Guidelines on Good Distribution Practice (GDP), including Annexes 15 and 16.

Author: MHRA


Publisher: Pharmaceutical Press

ISBN: 9780857114396

Price: £82

Format: Paperback 244 x 172mm

Extent: 1140pp



Rules and Guidance for Pharmaceutical Distributors 2022 The Green Guide

This new 2017 edition provides you with a single source of guidance to, and legislation for, the distribution of medicines in Europe and the UK. This tenth edition has been updated to incorporate the revised EU Guidelines on Good Distribution Practice.

The Green Guide reproduces all the elements of the new Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017 (the Orange Guide) that are relevant to distributors. So if you're involved in the wholesale supply, distribution and

brokering of medicines for human use and the distribution of active substances, this is the one-stop guide you need.

Author: MHRA


Publisher: Pharmaceutical Press

ISBN: 9780857114419

Price: £72

Format: Paperback 244 x 172mm

Extent: 400pp



Good Clinical Practice Guide

This detailed and authoritative guide covers the legislation, guidance and good practice that relates to the conduct of clinical trials of medicinal products for human use in the UK. It references European and international standards so will also be relevant to organisations conducting trials across Europe and beyond.

Written and produced by the MHRA, this is the only guide on Good Clinical Practice available within Europe which has been produced by a regulatory agency.

Author: MHRA

Publisher: Pharmaceutical Press

ISBN: 9780117081079

Price: £45

Format: Paperback 244 x 172mm

Extent: 542pp





 **tso**
a Williams Lea company